# Eli Lilly 宣布其標靶療法 Retevmo（selpercatinib）顯著降低早期 RET 融合陽性非小細胞肺癌患者的疾病復發或死亡風險。

*biotech · news · 2026-05-31 · NDTV Profit*

## Key points

- Retevmo 將早期 RET 陽性非小細胞肺癌患者的復發或死亡風險降低了 83%。
- LIBRETTO-432 是首個在輔助治療環境中進行的選擇性 RET 抑制劑隨機第三期臨床試驗。
- 在 II 至 IIIA 期患者中，使用 Retevmo 的 24 個月無事件生存率為 92%，而安慰劑組為 61%。
- RET 融合現被視為與 EGFR 突變和 ALK 融合並列的早期肺癌關鍵可操作生物標誌。
- Lilly 計劃向監管機構提交試驗數據，可能將 Retevmo 建立為新的標準治療方案。

In a promising breakthrough for lung cancer treatment, Eli Lilly announced that its targeted therapy Retevmo (selpercatinib) significantly reduced the risk of disease recurrence or death in patients with early-stage RET fusion-positive non-small cell lung cancer (NSCLC), according to results from a Phase 3 clinical trial. The LIBRETTO-432 study found that patients treated with Retevmo after surgery or radiation therapy experienced an 83% lower risk of cancer recurrence or death compared with those receiving a placebo, according to a press release. The trial involved 151 patients with stage IB-IIIA RET fusion-positive NSCLC and is the first randomized Phase 3 study to evaluate a selective RET inhibitor in the adjuvant setting. According to the company, event-free survival rates at 24 months reached 92% among patients with stage II-IIIA disease who received Retevmo, compared with 61% in the placebo group. ALSO READ : India, Oman Trade Pact To Come Into Force From June 1: An Explainer Similar benefits were observed across the broader study population, reinforcing the drug's potential role in preventing cancer relapse. The findings, which will be presented at the 2026 Annual Meeting of the American Society of Clinical Oncology and published in the New England Journal of Medicine, highlight the growing importance of comprehensive genomic testing in lung cancer diagnosis. Researchers said the results place RET fusions alongside EGFR mutations and ALK fusions as key biomarkers that can be effectively targeted in early-stage lung cancer. While overall survival data remain immature, early trends also favoured Retevmo. ALSO READ : 'No Trust In Promises': Iran's Chief Negotiator Rules Out US Deal Without Tangible Results Lilly said it plans to submit the trial data to global regulatory authorities, a move that could pave the way for Retevmo to become a new standard treatment option for patients with early-stage RET-positive lung cancer.

**Companies:** Eli Lilly

[Read the full story on NDTV Profit](https://www.ndtvprofit.com/science/eli-lilly-s-retevmo-cuts-lung-cancer-recurrence-risk-by-83-in-phase-3-trial-11572023)

---

Canonical: https://newsio.io/zh-TW/n/233d595d-f0a4-4fab-a7f9-3cfb951c4ea5/eli-lilly-retevmoselpercatinib-ret
Summarized by Newsio from NDTV Profit. https://newsio.io/how-it-works